Does Medicare Cover Weight Loss Medication?

Summary: Medicare Part D excludes weight loss drugs under a 2003 statute, but Wegovy is covered for cardiovascular risk reduction and Zepbound for obstructive sleep apnea when the prescribing paperwork is built correctly.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The short answer: Medicare does not cover medication for weight loss alone. A 2003 statute blocks Part D from paying for anything prescribed solely to drop weight. The workarounds are real but narrow. Wegovy is covered when a cardiologist prescribes it for cardiovascular risk reduction in patients with established heart disease. Zepbound is covered when a sleep physician prescribes it for moderate to severe obstructive sleep apnea in patients with obesity. Everything else still requires a different FDA-approved diagnosis, a Medicare Advantage plan with a supplemental obesity benefit, or out-of-pocket cash. A 2026 CMS demonstration called the GLP-1 Bridge will add a $50 monthly copay option starting July 1, 2026, with its own clinical criteria.

This page walks through the law, the carve-outs, the plan-level variation, and the documentation that gets a claim paid instead of denied.

The statute that blocks coverage

When Congress created Part D in the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, it copied a list of excluded drug categories straight from the Medicaid program. One of those categories is "agents when used for anorexia, weight loss, or weight gain." That language sits in section 1860D-2(e)(2)(A) of the Social Security Act, and it has not changed since 2003. As long as it stays on the books, Part D plans cannot count weight-loss drugs toward the basic benefit, the deductible, or the $2,000 annual out-of-pocket cap that the Inflation Reduction Act created in 2025.

The exclusion is about the indication on the prescription, not the molecule. Semaglutide, the active ingredient in Wegovy, is the same molecule as in Ozempic. Ozempic is covered for type 2 diabetes because diabetes is not on the excluded list. Wegovy was not coverable at all until the FDA added a non-weight indication to its label in 2024. Same drug, same dose range, different label sentence, different coverage answer.

The Wegovy carve-out for cardiovascular disease

In March 2024, CMS issued a Health Plan Management System (HPMS) memo to all Part D sponsors clarifying that anti-obesity medications with an additional medically accepted indication are no longer excluded under the statute when prescribed for that other indication ^[1]. The memo was triggered by the FDA's March 8, 2024 label update for Wegovy. That update added a new indication: reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease who are also overweight or obese.

The label change rests on SELECT, the cardiovascular outcomes trial Novo Nordisk ran from 2018 to 2023. SELECT enrolled 17,604 adults aged 45 and older with a BMI of 27 or higher who had prior myocardial infarction, prior stroke, or symptomatic peripheral artery disease and no history of diabetes. After a mean follow-up of 39.8 months, the primary composite endpoint of cardiovascular death, non-fatal MI, or non-fatal stroke occurred in 6.5 percent of the semaglutide group versus 8.0 percent of the placebo group, a 20 percent relative risk reduction with a p-value below 0.001 ^[2]. The hazard ratio was 0.80 with a 95 percent confidence interval of 0.72 to 0.90. That is the trial that opened the door.

The March 2024 CMS memo told plans that they "may add" Wegovy to formularies for this indication. It did not require them to. So whether your specific Part D plan or Medicare Advantage prescription drug plan covers Wegovy depends on the plan's 2026 formulary decision. Most major plans added it. Some did not. Some added it with step therapy requiring documentation of statin and antiplatelet use first. Check your plan's formulary by NDC before assuming.

What the cardiologist documentation needs to show

A prior authorization for Wegovy under the cardiovascular indication has to attest to three things:

1. Established cardiovascular disease, defined the same way SELECT defined it: prior myocardial infarction, prior ischemic stroke, or symptomatic peripheral artery disease. Hypertension alone does not qualify. Elevated LDL alone does not qualify. The plan wants an event or a documented vascular diagnosis.
2. BMI of 27 or higher at the time the prescription is initiated. Plans typically accept a clinic measurement within the prior 90 days.
3. The prescriber's intent is cardiovascular risk reduction, not weight loss. The Wegovy claim has to be paired with the cardiovascular ICD-10 code (typically I25.10 for atherosclerotic heart disease, I63 series for stroke history, I73.9 for peripheral artery disease), not E66 for obesity.

If your primary care doctor is the only one prescribing Wegovy and the claim lists E66.01 (morbid obesity) as the primary code, the plan will deny it as a weight-loss indication regardless of your cardiovascular history. The cardiology note in the chart is what backs up the appeal if the first claim is rejected.

The Zepbound carve-out for obstructive sleep apnea

On December 20, 2024, the FDA approved Zepbound for the treatment of moderate to severe obstructive sleep apnea in adults with obesity. Zepbound became the first drug ever approved for OSA. The approval rested on SURMOUNT-OSA, two parallel phase 3 trials that enrolled 469 adults with moderate-to-severe OSA (apnea-hypopnea index of 15 or higher) and a BMI of 30 or higher. At 52 weeks, tirzepatide reduced the apnea-hypopnea index by 25.3 events per hour in the trial of patients not using PAP therapy and by 29.3 events per hour in the trial of patients on PAP, compared to placebo reductions of roughly 5 events per hour ^[3]. Both p-values were below 0.001.

The OSA approval flipped Zepbound into the same coverage bucket as Wegovy. Part D plans may now cover Zepbound for OSA in patients with obesity, and the coverage is for the OSA diagnosis, not weight loss. The same March 2024 CMS framework applies. Plans are not required to add it, but most national formularies did so for the 2026 plan year.

What the sleep apnea documentation needs to show

The prior authorization for Zepbound under the OSA indication needs:

1. A polysomnography or home sleep apnea test with an apnea-hypopnea index of 15 or higher, scored by a sleep physician within the look-back window the plan specifies (commonly 12 months).
2. BMI of 30 or higher at the time of prescription.
3. The prescribing diagnosis coded as G47.33 (obstructive sleep apnea) rather than E66.

CPAP intolerance is not required for the FDA label, and the SURMOUNT-OSA trials included both PAP users and non-users. Some plans add a step requiring documentation of CPAP trial or intolerance before approving Zepbound. Read your plan's specific UM criteria.

Other weight-related drugs that Medicare sometimes does cover

The 2003 exclusion has been read narrowly by some plans, and a few older anti-obesity drugs slip through plan formularies under specific clinical scenarios.

Phentermine is the case that surprises people. It is technically a Schedule IV anorectic, which puts it on the excluded list when used for weight loss. But a small subset of Medicare Advantage plans and some standalone PDPs cover phentermine under exception processes when the prescriber documents a non-weight indication, typically attention or fatigue secondary to a specific medical condition. This is rare, plan-specific, and not a strategy to count on. Generic phentermine cash prices at GoodRx are low enough (often under $20 for a 30-day supply) that most patients pay out of pocket rather than fight a coverage denial.

Medicare Advantage plan variability

Original Medicare (Parts A and B) does not cover any outpatient prescription drugs. Drug coverage comes from either a standalone Part D plan layered onto Original Medicare or from a Medicare Advantage prescription drug plan (MA-PD). Medicare Advantage plans are run by private insurers under CMS contracts, and they have latitude to offer "supplemental benefits" that go beyond what Original Medicare covers.

A handful of Medicare Advantage plans, particularly Special Needs Plans (SNPs) for people with chronic conditions or dual eligibility, have started offering weight-management drug benefits as part of their supplemental package. These benefits are usually capped, limited to one or two drugs from the plan's selection, and require enrollment in the plan's chronic care management program. They are also subject to change every plan year, so a benefit offered in 2026 is not guaranteed for 2027.

Kaiser Permanente Medicare Advantage plans, Aetna Medicare Advantage, UnitedHealthcare Medicare Advantage, Humana Medicare Advantage, and BCBS Medicare Advantage plans all approach the GLP-1 question differently across their regional plan offerings. Even within one insurer, the answer can be different in California than in Florida. The only reliable source is the specific Evidence of Coverage document for your specific plan in your specific county for the current plan year. Search the plan's drug formulary by name (Wegovy, Zepbound) before signing up.

The TROA legislative debate

The Treat and Reduce Obesity Act, usually called TROA, has been introduced in every Congress since 2012. The most recent version, H.R. 4818 in the 118th Congress, would have amended section 1860D-2(e)(2)(A) of the Social Security Act to explicitly allow Part D coverage of FDA-approved drugs for chronic weight management in adults ^[5]. It carried bipartisan sponsorship but never received a floor vote.

The reason TROA has stalled for over a decade is cost. The Congressional Budget Office scored expansion of Medicare GLP-1 coverage at $35 billion over the 2026 to 2034 window in its most recent estimate. With more than 40 percent of US adults aged 60 and older meeting BMI criteria for treatment, even modest uptake at current list prices would dwarf existing Part D spending categories. Lawmakers who support TROA in principle have been waiting either for cheaper generics, for the Inflation Reduction Act drug price negotiation process to push GLP-1 prices down, or for political cover from a CMS demonstration that would absorb the initial cost.

That CMS demonstration arrived in December 2025.

The Medicare GLP-1 Bridge demonstration

On December 23, 2025, CMS announced a short-term demonstration called the Medicare GLP-1 Bridge that runs from July 1, 2026 through December 31, 2027 ^[4]. The Bridge operates outside the Part D benefit's normal coverage and payment flow, using a single central processor (Humana, drawing on its existing LI NET program infrastructure) to handle prior authorization, claims adjudication, and pharmacy payment.

Eligible patients pay a flat $50 monthly copay for a covered GLP-1 product. As of the April 2026 update, the eligible drug list includes all formulations of Wegovy, all formulations of Foundayo, and the KwikPen formulation of Zepbound. The single-dose vial and single-dose pen formulations of Zepbound are excluded from the Bridge.

The clinical eligibility criteria are stricter than the FDA labels. To qualify, a beneficiary must be at least 18, be enrolled in an eligible Part D plan type, and meet one of these three tiers:

• BMI of 35 or higher at the time of GLP-1 therapy initiation, with no additional diagnosis required.
• BMI of 30 to 34.9 at initiation, plus heart failure with preserved ejection fraction, uncontrolled hypertension on two antihypertensives, or chronic kidney disease stage 3a or higher.
• BMI of 27 to 29.9 at initiation, plus pre-diabetes, prior myocardial infarction, prior stroke, or symptomatic peripheral artery disease.

A few things that confuse people about the Bridge: the $50 copay does not count toward the Part D $2,000 out-of-pocket cap. Manufacturer coupons and discount cards cannot stack on top of the Bridge price. And patients who already qualify for Wegovy under the cardiovascular Part D pathway or Zepbound under the OSA Part D pathway are supposed to stay on those pathways rather than shift to the Bridge. The Bridge is for patients whose primary indication is weight management itself.

How to navigate coverage for your situation

Step 1: identify which pathway you qualify for

You have established cardiovascular disease (prior MI, stroke, or PAD) and a BMI of 27 or higher? Wegovy under the Part D cardiovascular pathway is your first option. Get a cardiologist note documenting the qualifying event and current BMI, and ask the cardiologist to write the prescription with the cardiovascular ICD-10 code.

You have moderate to severe OSA (AHI of 15 or higher) and a BMI of 30 or higher? Zepbound under the Part D OSA pathway. Get a current sleep study and have the sleep physician write the prescription with G47.33 as the primary diagnosis.

You have type 2 diabetes? Ozempic, Mounjaro, Rybelsus, and Trulicity are all on standard Part D formularies for diabetes. Coverage is straightforward, though prior authorization and step therapy through metformin are common.

You do not have any of the above but you meet the GLP-1 Bridge BMI criteria? Wait until July 1, 2026 and ask your prescriber to submit a Bridge prior authorization through Humana's central processor. The $50 copay is the lowest cost option for weight-loss-indicated GLP-1 use in Medicare for the duration of the demonstration.

You do not qualify for any of the pathways above? Out-of-pocket cash through manufacturer programs (Wegovy NovoCare and Zepbound's vial program both list at $499 per month for self-pay) or GoodRx-style discount cards for generics like phentermine are the remaining options.

Step 2: build the documentation before the prior authorization

Plans deny first prior authorizations as a default. The denial rate on Wegovy PAs under the cardiovascular indication in the first quarter after the March 2024 memo ran above 50 percent at several major plans because the initial submissions did not clearly separate the cardiovascular indication from the weight-loss indication. Successful PAs include:

• The qualifying clinical event with date, facility, and ICD-10 code.
• A current BMI with the measurement date.
• A clear statement from the prescriber that the medication is being initiated for the non-weight-loss indication.
• Any required prior trial documentation (e.g., statin and antiplatelet history for cardiovascular indication).

Step 3: appeal denials

Medicare Part D appeals follow a defined path. Tier 1 is a coverage determination request, which the plan must answer within 72 hours of receiving it (24 hours for expedited requests). Tier 2 is a redetermination by the plan. Tier 3 is independent review by a CMS-contracted entity. Most legitimate Wegovy and Zepbound denials get overturned at Tier 2 or Tier 3 if the documentation is correct. The plan rejection letter will list the specific deficiency, which is usually missing diagnosis documentation or missing trial-and-failure documentation for required step therapy.

What about Medicaid, TRICARE, and commercial plans

Medicaid coverage of weight-loss drugs is state-by-state. As of 2026, fewer than 20 state Medicaid programs cover GLP-1s for weight loss. Most cover them only for type 2 diabetes. North Carolina, Pennsylvania, and Michigan have meaningful weight-loss coverage; many southern and mountain west states do not. Medicaid also covers bariatric surgery in most states when the patient meets standard NIH criteria (BMI of 40, or BMI of 35 with comorbidities).

TRICARE covers GLP-1s for type 2 diabetes across all plan types. For weight loss, TRICARE Select and TRICARE Prime began covering Wegovy and Zepbound in 2024 with prior authorization based on BMI and at least one comorbidity. TRICARE for Life beneficiaries who also have Medicare follow the Medicare rules above for primary coverage.

Commercial coverage at Blue Cross Blue Shield, Aetna, UnitedHealthcare, and Kaiser varies by employer group and plan year. Self-insured employer plans set their own GLP-1 coverage rules; the insurer's name on the card does not determine the answer. Federal Employees Health Benefits Program plans (including BCBS Federal) cover GLP-1s for weight loss with prior authorization and BMI requirements, though some plans tightened criteria for the 2026 plan year. HSA and FSA dollars can pay for GLP-1s with a letter of medical necessity even when the underlying plan does not cover them, which lowers the effective cost by the patient's marginal tax rate.

Common questions about Medicare and weight loss medication

Does Medicare cover Wegovy for weight loss?

No. Medicare covers Wegovy only for cardiovascular risk reduction in patients with established cardiovascular disease and BMI of 27 or higher, per the March 2024 CMS clarification memo. Coverage for weight loss alone remains blocked by the 2003 statute.

Does Medicare cover Zepbound for weight loss?

No, but Medicare may cover Zepbound for moderate to severe obstructive sleep apnea in adults with obesity, following the FDA's December 2024 OSA approval and the same CMS framework that opened the Wegovy carve-out.

Does Medicare cover Ozempic?

Yes, for type 2 diabetes. Ozempic is on every major Part D plan formulary for diabetes management. It is not covered for weight loss.

When will Medicare cover weight loss drugs broadly?

Broad coverage requires Congress to amend the 2003 statute, which the Treat and Reduce Obesity Act would do. In the meantime, the CMS GLP-1 Bridge demonstration provides $50 copay access from July 1 2026 through December 31 2027 for eligible beneficiaries.

Does Medicaid pay for weight loss drugs?

Some state Medicaid programs cover GLP-1s for weight loss; most cover them only for type 2 diabetes. Coverage varies state by state. Bariatric surgery is covered by Medicaid in most states when standard BMI and comorbidity criteria are met.

Does TRICARE cover GLP-1 for weight loss?

TRICARE Select and TRICARE Prime cover Wegovy and Zepbound for weight loss with prior authorization based on BMI and comorbidities. TRICARE Pharmacy at military treatment facilities and home delivery have the lowest copays.

Does Blue Cross Blue Shield Federal cover weight loss drugs?

BCBS Federal Employee Program plans cover GLP-1s for weight loss with prior authorization. The 2026 plan year tightened BMI and step therapy requirements at several plan tiers. Read the FEHB brochure for your specific plan.

Does Aetna cover GLP-1 for weight loss?

Aetna commercial coverage depends on the employer group; many cover Wegovy and Zepbound with prior authorization. Aetna Medicare Advantage plans follow Medicare rules and cover these drugs only under the cardiovascular or OSA indications.

Does UHC cover weight loss drugs?

UnitedHealthcare commercial plan coverage varies by employer. UHC Medicare Advantage plans cover Wegovy and Zepbound only under the cardiovascular and OSA carve-outs, the same as other Medicare plans.

Does Kaiser cover weight loss medication?

Kaiser Permanente plans vary by region. Kaiser commercial coverage often requires participation in a structured weight management program before approving GLP-1s. Kaiser Medicare Advantage follows the same Medicare carve-out framework.

Will Medicaid cover weight loss surgery?

Yes, in most states, when the patient meets NIH-standard criteria: BMI of 40, or BMI of 35 with at least one obesity-related comorbidity such as type 2 diabetes, hypertension, or OSA. Coverage requires use of a Medicaid-approved bariatric center.

Can I use HSA or FSA dollars for weight loss medication?

Yes, with a letter of medical necessity from your prescriber. Both HSA and FSA funds can pay for FDA-approved weight loss medications. HSA dollars roll over year to year; FSA dollars are use-it-or-lose-it.

Are the $99 per month telehealth weight loss programs legitimate?

Most $99 monthly telehealth offers are compounded semaglutide or tirzepatide from 503A or 503B pharmacies, not the FDA-approved brand products. Quality and consistency vary widely. Verify the pharmacy's state licensure and ask about USP 797 sterile compounding certification before enrolling.

How does GoodRx work for weight loss drugs?

GoodRx provides cash discount cards that bring down out-of-pocket prices at retail pharmacies. For brand GLP-1s like Wegovy and Zepbound, GoodRx discounts are smaller than the manufacturers' direct-to-patient programs (NovoCare and LillyDirect), which typically list at $499 monthly for cash-pay patients.

The 30-second decision tree

Established cardiovascular disease plus BMI 27 or higher: ask your cardiologist about Wegovy under the Part D cardiovascular pathway.

Moderate-severe OSA plus BMI 30 or higher: ask your sleep doctor about Zepbound under the Part D OSA pathway.

Type 2 diabetes: Ozempic, Mounjaro, Rybelsus, or Trulicity through standard Part D coverage.

None of the above, but BMI 27 or higher with a qualifying comorbidity, or BMI 35 or higher with nothing else: wait for the GLP-1 Bridge ($50/month) starting July 1, 2026.

Nothing fits and you need a drug now: manufacturer cash programs at $499/month, or compounded semaglutide and tirzepatide through licensed pharmacies with the documentation caveats above.

The 2003 statute is the wall. The carve-outs and the Bridge are the doors. The right door depends on which diagnosis you actually have on paper.